Auspherix Nabs £6M for Fight Against Antimicrobial Resistance
June 04, 2015
Auspherix, a company developing drugs to fight antimicrobial resistance, has raised £6 million in Series A financing led by Imperial Innovations. Capital from the round will be used to fund the company's drug discovery program and help progress its antibacterials through the process of lead optimization to final candidate selection. Innovations invested £3 million in the round and now holds a 27.5% stake.